Australian Study Finds First-Line Pembrolizumab Exceeds Cost-Effectiveness Thresholds in Lung Cancer
A health economic evaluation in Australia demonstrates that first-line pembrolizumab monotherapy for advanced non-small cell lung cancer yields incremental cost-effectiveness ...




